Differences in ventilatory inefficiency between pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

Chest

Volumn 140, Issue 5, 2011, Pages 1284-1291

  Zhai, Zhenguo ^a,d   Murphy, Kevin ^e   Tighe, Hannah ^e   Wang, Chen ^d   Wilkins, Martin R ^b   Gibbs, J Simon R ^c   Howard, Luke S ^c  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN DERIVATIVE;

ADULT; ARTICLE; BLOOD GAS ANALYSIS; CARDIOPULMONARY EXERCISE TEST; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; END TIDAL CARBON DIOXIDE TENSION; FEMALE; HUMAN; LUNG DEAD SPACE; LUNG GAS EXCHANGE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RESPIRATORY FUNCTION; RETROSPECTIVE STUDY;

EID: 81055126054     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-3357     Document Type: Article

References (29)

1. Ferrazza AM, Martolini D, Valli G, Palange P. Cardiopulmonary exercise testing in the functional and prognostic evaluation of patients with pulmonary diseases. Respiration. 2009; 77(1):3-17.
2. Guazzi M, Arena R. The impact of pharmacotherapy on the cardiopulmonary exercise test response in patients with heart failure: a mini review. Curr Vasc Pharmacol. 2009;7(4):557-569.
3. Arena R, Myers J, Guazzi M. The clinical and research applications of aerobic capacity and ventilatory efficiency in heart failure: an evidence-based review. Heart Fail Rev. 2008;13(2):245-269.
4. Groepenhoff H, Vonk-Noordegraaf A, Boonstra A, Spreeuwenberg MD, Postmus PE, Bogaard HJ. Exercise testing to estimate survival in pulmonary hypertension. Med Sci Sports Exerc. 2008;40(10):1725-1732.
5. Hoeper MM, Pletz MW, Golpon H, Welte T. Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2007;29(5):944-950. (Pubitemid 46711899)
6. Yasunobu Y, Oudiz RJ, Sun XG, Hansen JE, Wasserman K. End-tidal PCO2 abnormality and exercise limitation in patients with primary pulmonary hypertension. Chest. 2005;127(5): 1637-1646. (Pubitemid 46218789)
7. Wensel R, Opitz CF, Anker SD, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation. 2002;106(3):319-324. (Pubitemid 34778955)
8. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Exercise pathophysiology in patients with primary pulmonary hypertension . Circulation. 2001;104(4):429-435. (Pubitemid 32678273)
9. Kapitan KS, Buchbinder M, Wagner PD, Moser KM. Mechanisms of hypoxemia in chronic thromboembolic pulmonary hypertension. Am Rev Respir Dis. 1989;139(5):1149-1154. (Pubitemid 19139836)
10. Dantzker DR, D'Alonzo GE, Bower JS, Popat K, Crevey BJ. Pulmonary gas exchange during exercise in patients with chronic obliterative pulmonary hypertension. Am Rev Respir Dis. 1984;130(3):412-416. (Pubitemid 14029769)
11. D'Alonzo GE, Gianotti LA, Pohil RL, et al. Comparison of progressive exercise performance of normal subjects and patients with primary pulmonary hypertension. Chest. 1987;92(1):57-62. (Pubitemid 17101336)
12. Galiè N, Hoeper MM, Humbert M, et al. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009;34(6):1219-1263.
13. American Thoracic Society; American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003;167(2):211-277.
14. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111-117.
15. Naeije R, van de Borne P. Clinical relevance of autonomic nervous system disturbances in pulmonary arterial hypertension . Eur Respir J. 2009;34(4):792-794.
16. Sun XG, Hansen JE, Garatachea N, Storer TW, Wasserman K. Ventilatory efficiency during exercise in healthy subjects. Am J Respir Crit Care Med. 2002;166(11):1443-1448. (Pubitemid 35387293)
17. Wagner PD. The multiple inert gas elimination technique (MIGET). Intensive Care Med. 2008;34(6):994-1001.
18. Dantzker DR, Bower JS. Mechanisms of gas exchange abnormality in patients with chronic obliterative pulmonary vascular disease. J Clin Invest. 1979;64(4):1050-1055. (Pubitemid 10232583)
19. Delcroix M, Mélot C, Vachiéry JL, et al. Effects of embolus size on hemodynamics and gas exchange in canine embolic pulmonary hypertension. J Appl Physiol. 1990;69(6):2254-2261.
20. Raffestin B, Leroy M. Clinical relevance of autonomic nervous system disturbances in pulmonary arterial hypertension. Eur Respir J. 2010;35(3):704-705.
21. Tumminello G, Guazzi M, Lancellotti P, Piérard LA. Exercise ventilation inefficiency in heart failure: pathophysiological and clinical significance. Eur Heart J. 2007;28(6):673-678. (Pubitemid 46439224)
22. Dimopoulos S, Anastasiou-Nana M, Katsaros F, et al. Impairment of autonomic nervous system activity in patients with pulmonary arterial hypertension: a case control study. J Card Fail. 2009;15(10):882-889.
23. Wensel R, Jilek C, Dörr M, et al. Impaired cardiac autonomic control relates to disease severity in pulmonary hypertension. Eur Respir J. 2009;34(4):895-901.
24. Ciarka A, Doan V, Velez-Roa S, Naeije R, van de Borne P. Prognostic significance of sympathetic nervous system activation in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010;181(11):1269-1275.
25. Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, van de Borne P. Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation. 2004;110(10):1308-1312. (Pubitemid 39202350)
26. Ingle L. Prognostic value and diagnostic potential of cardiopulmonary exercise testing in patients with chronic heart failure. Eur J Heart Fail. 2008;10(2):112-118.
27. Valli G, Vizza CD, Onorati P, et al. Pathophysiological adaptations to walking and cycling in primary pulmonary hypertension . Eur J Appl Physiol. 2008;102(4):417-424.
28. Jaïs X, D'Armini AM, Jansa P, et al.; Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT(Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008; 52(25):2127-2134.
29. West JB. Ventilation-perfusion inequality and overall gas exchange in computer models of the lung. Respir Physiol. 1969;7(1):88-110.